Receive The Newest Study Notifications

Prototype web portal shows technology's potential to protect and streamline the clinical trials process UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an...

Developed by researchers at the University of Turku in Finland, an immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumours in several mouse models. The...

A new "smart drug" has shown promise for women with metastatic triple-negative breast cancer, based on data from a clinical trial at NewYork-Presbyterian/Columbia's Herbert Irving Comprehensive Cancer Center and other centers. The data from the trial were published...

Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Renji Hospital, today announced a collaboration to conduct a clinical trial into the early detection of lung cancer...

- STS101 for the acute treatment of migraine demonstrates highly differentiated pharmacokinetic (PK) profile in Phase 1 clinical trial - Satsuma successfully completes FDA meeting, establishing key elements of the STS101 Phase 3 development program to support NDA -...

The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile...

-- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced interim...

Unique collaboration pairs HLT’s data technology and artificial intelligence with PPD’s global expertise in clinical trials and real-world evidence generation Pharmaceutical Product Development, LLC (PPD) and Happy Life Tech (HLT) of China have signed an exclusive...

Verisense was designed specifically to improve data quality in clinical trials, while reducing burden on sponsors, sites and participants Shimmer, a global leader in wearable technology for research applications, has announced the launch of Verisense, its...

Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, announced today that the first patient has been treated in a Phase 1 clinical trial to evaluate...

Combination trial to evaluate safety and anti-tumor activity of agents that target B-cell cancers ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced...

- Phase 1/2 combination clinical trial evaluating Torque's Deep IL-15 Primed T Cells (TRQ-1501) and KEYTRUDA® (pembrolizumab) for the treatment of multiple cancer indications - Torque, a clinical-stage immuno-oncology company developing first-in-class Deep Primed™ T...

Initial top line data of MS1819-SD in Cystic Fibrosis Patients expected in mid-2019. First patients dosed in open-label, cross-over Phase II OPTION study with MS1819-SD for exocrine pancreatic insufficiency in cystic fibrosis. Five clinical trial sites in the U.S....

The Heart Failure Society of America (HFSA) and XpertDox today announced the launch of the XpertDox product, XpertTrialTM, a clinical trial search and engagement platform. The XpertTrial platform will provide patients and providers with the most up-to-date information...

Study complements ongoing trial in the prodromal to mild population AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that Genentech, a member of the Roche...

- Troriluzole is a third-generation tripeptide prodrug and new chemical entity that modulates glutamate, the most abundant excitatory neurotransmitter in the human body - The therapeutic potential of troriluzole in GAD is supported by clinical and translational...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S. Food and Drug Administration (FDA) has...

Alex Keown writes: There could a new form of treatment in Japan for spinal cord injuries if a newly-approved clinical trial hits the mark.   On Monday, a special committee of the Ministry of Health, Labor and Welfare in Japan approved a clinical research program...

DAIX, France I February 18, 2019 I Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced the...

-- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, today announced...